Sartorius stock trades at EUR 253.60 as guidance stays firm

Sartorius stock was trading at EUR 253.60 on Xetra on September 24, 2026, with the session change at 0.00 percent. The company enters the next reporting phase with 2026 sales guidance of 5 percent to 9 percent still in place.

Guidance covers 5 percent to 9 percent

According to Yahoo Finance in the Q2/2026 earnings call, Sartorius reported first-half sales growth of 7.7 percent on an operational basis in constant currencies. The figure gives the recovery story a measurable base rather than leaving the outlook dependent on a single quarterly data point.

The company also confirmed guidance for group sales growth of 5 percent to 9 percent in constant currencies and an underlying EBITDA margin above 30 percent for 2026. Bioprocess Solutions carries a 6 percent to 10 percent growth range, while Lab Products and Services is guided to 2 percent to 6 percent.

EBITDA rises 3.9 percent

Underlying EBITDA increased 3.9 percent to EUR 548 million in the first six months of 2026, while the underlying EBITDA margin improved by 50 basis points to 30.3 percent, according to Yahoo Finance.

For investors, the margin is the key operating measure. The comparison between 3.9 percent EBITDA growth and the 30.3 percent margin shows that profitability improved alongside sales, although the full-year outcome still depends on the second-half development.

Deutsche Bank targets EUR 284

On September 22, 2026, Deutsche Bank retained its Buy rating and a EUR 284 price target for Sartorius, as reported by MarketScreener. The target is EUR 30.40 above the Xetra price of EUR 253.60, while the next scheduled earnings release is October 21, 2026.

Xetra price stays at EUR 253.60

Sartorius stock stood at EUR 253.60 on Xetra on September 24, 2026. The unchanged session leaves the confirmed guidance, the 30.3 percent first-half margin and the October 21 reporting date as the clearest near-term reference points.